

## Press Release

**Nicole Weber**  
Corporate Communications

Fresenius SE & Co. KGaA  
Else-Kröner-Straße 1  
61352 Bad Homburg  
Germany  
T +49 6172 686-2394  
nicole.weber@fresenius.com  
www.fresenius.de

May 29, 2024

### **Fresenius Appoints Internationally Experienced Biopharma Expert to the Fresenius Kabi Management Board**

- Dr. Sang-Jin Pak takes over the management of the Biopharma business at Fresenius Kabi
- Dr. Michael Schönhofen, Head of Biopharma and member of the Fresenius Kabi Management Board, leaves the company after more than 30 successful years

Dr. Michael Schönhofen, Head of the Biopharma business on the Fresenius Kabi Management Board, will leave the company on June 30, 2024, after more than 30 successful years. His responsibilities will be taken over by Dr. Sang-Jin Pak. The Supervisory Board has appointed him to the Fresenius Kabi Management Board with effect from June 1, 2024, thus ensuring a smooth transition.

Michael Sen, Fresenius CEO and Chairman of the Fresenius Kabi Supervisory Board: "Biopharma performed excellently in the first quarter of this year. With the rapid launch of our biosimilar Tyenne for the treatment of inflammatory and autoimmune diseases in the EU and the USA, we have also recently achieved two major milestones. I would like to thank Dr. Michael Schönhofen from the bottom of my heart for his tireless commitment and his excellent work and wish him all the best for the future. At the same time, I am delighted that we have been able to appoint Dr. Sang-Jin Pak, a recognized and proven biopharma expert with extensive international management experience, to help us further develop the innovative strength and momentum of our Biopharma platform."

“Dr. Michael Schönhofen has made an outstanding contribution to the expansion of our Biopharma business into one of the three #FutureFresenius growth platforms. The seamless transition at the top of our Biopharma platform will provide the continuity needed to further increase our innovative strength and momentum,” added Pierluigi Antonelli, Fresenius Kabi CEO and member of the Fresenius Management Board.

Dr. Michael Schönhofen began his career in 1991 as head of the dialyzers business unit at Fresenius Medical Care. After working in St. Wendel in Saarland, Germany and in Ogden, Utah, USA, where he was responsible for setting up the plant, he took over responsibility for the disposables business unit for Europe, Asia, the Middle East, and Latin America in 2000. Dr. Michael Schönhofen has been a member of the Fresenius Kabi Management Board since 2004.

Dr. Sang-Jin Pak will join the Fresenius Kabi Management Board on June 1, 2024, and will be based in Bad Homburg, Germany. Dr. Sang-Jin Pak joins the company from Samsung Bioepis, a leading biopharmaceutical company based in Seoul, Korea. He has been Executive Vice President of the Global Commercial business unit there since 2018. Prior to that, he was responsible for GlaxoSmithKline’s German business for five years and was Managing Director of AstraZeneca in Korea from 2010 to 2013. Dr. Sang-Jin Pak studied medicine at Johannes Gutenberg University Mainz and healthcare management at the universities of Mannheim and Heidelberg.

# # #

Fresenius SE & Co. KGaA (Frankfurt/Xetra: FRE) is a global healthcare company headquartered in Bad Homburg v. d. Höhe, Germany. In the 2023 fiscal year, Fresenius generated €22.3 billion in annual revenue with its more than 190,000 employees. Fresenius offers solutions to the social challenges posed by a growing and aging population and the resulting need for affordable, high-quality healthcare. The Fresenius Group comprises the operating companies Fresenius Kabi and Fresenius Helios as well as the investment company Fresenius Medical Care. With 140 hospitals and countless outpatient facilities, Fresenius Helios is the leading private hospital operator in Germany and Spain, treating around 26 million patients every year. Fresenius Kabi’s product portfolio includes a range of highly complex biopharmaceuticals, clinical nutrition, medical technology, and generic intravenous drugs. Fresenius was established in 1912 by the Frankfurt pharmacist Dr. Eduard Fresenius. After his death, Else Kröner took over management of the company in 1952. She laid the foundations for a global enterprise that today pursues the goal of improving people’s health. The largest shareholder is the non-profit Else Kröner-Fresenius Foundation, which is dedicated to advancing medical research and supporting humanitarian projects.

For more information visit the company website at [www.fresenius.com](http://www.fresenius.com).  
Follow us on social media: [www.fresenius.com/socialmedia](http://www.fresenius.com/socialmedia)

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those currently expected due to various risk factors and uncertainties, e.g. changes in

business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, the availability of financing and unforeseen impacts of international conflicts. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA

Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11852

Chairman of the Supervisory Board: Wolfgang Kirsch

General Partner: Fresenius Management SE

Registered Office: Bad Homburg, Germany / Commercial Register: Amtsgericht Bad Homburg, HRB 11673

Management Board: Michael Sen (Chairman), Pierluigi Antonelli, Sara Hennicken, Robert Möller, Dr. Michael Moser

Chairman of the Supervisory Board: Wolfgang Kirsch